Cancer News and Research

Latest Cancer News and Research

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

In a recent study initiated by Beiersdorf AG, Florian Spörl and colleagues evaluated the use of Roche Applied Science's xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes.

1 Apr 2010

Thomson Reuters selects Rush University Medical Center as one of 100 Top Hospitals in the U.S.

Rush University Medical Center was selected as one of the 100 Top Hospitals in the United States by Thomson Reuters. The annual Thomson Reuters 100 Top Hospitals National Benchmarks study identifies the 100 best U.S. hospitals based on their overall organizational performance. Rush was one of only 15 major teaching hospitals in the country to be named.

1 Apr 2010

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Technical improvements to a microchip-based device for detecting and analyzing tumor cells in the bloodstream are revealing cellular differences that may reflect a tumor's aggressiveness and long-term response to treatment.

1 Apr 2010

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

1 Apr 2010

Link between occupational exposures and postmenopausal breast cancer

Occupational exposure to certain chemicals and pollutants before a woman reaches her mid-30s could treble her risk of developing cancer after the menopause, suggests research published in Occupational and Environmental Medicine .

1 Apr 2010

Dutasteride reduces risk of prostate cancer

There is good news for those at high risk for prostate cancer. The drug dutasteride which is manufactured by GlaxoSmithKline as the drug Avodart, has been found to reduce the risk of prostate cancer by a quarter. The drug is at present being used to treat enlarged prostates.

1 Apr 2010

Hormone ghrelin may improve appetite in gastric cancer patients

In gastric cancer patients who have had part or all of their stomach removed, the hormone ghrelin may lessen post-operative weight loss and improve appetite, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

1 Apr 2010

People in 60s and 70s more likely to be diagnosed with skin cancer

People in their 60s and 70s are now over five times more likely to be diagnosed with malignant melanoma - the deadliest type of skin cancer - than their parents would have been 30 years ago, reveal new Cancer Research UK statistics1 to launch the 2010 SunSmart campaign today (Thursday).

1 Apr 2010

RPCI selects McKesson to manage its medical billing processes

After a rigorous selection process, one of the nation's largest and most prestigious cancer centers, Roswell Park Cancer Institute, has selected McKesson to manage its medical billing processes. With McKesson's Revenue Management Solutions group taking over patient billing, accounts receivable management, and reporting, the New York-based education and research institute gains a partner that understands the complexities of its business.

1 Apr 2010

Positive results from Phase 2 clinical trial of OMS103HP

Omeros Corporation today announced that a Phase 2 clinical trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, demonstrated that patients treated with OMS103HP during arthroscopic knee meniscectomy surgery achieved statistically significant clinical benefits.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

Court rules against gene patents

The New York Times: A judicial ruling that "threw out parts of two gene patents and called into question thousands more" has biotechnology executives hastening "to reassure their investors that the ruling would not necessarily undermine their businesses, at least in the short run. But the executives themselves were struggling on Tuesday to figure out what the long-term impact would be."

1 Apr 2010

EMBL scientists identify genes involved in human cell division

Name a human gene, and you'll find a movie online showing you what happens to cells when it is switched off. This is the resource that researchers at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and their collaborators in the Mitocheck consortium are making freely available, as the result of a study in which they have identified the genes involved in mitosis - the most common form of cell division - in humans.

1 Apr 2010

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China with AXM Pharma, Inc.

1 Apr 2010

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b monotherapy study of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout. In this 28-day, randomized, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia (serum urate levels greater than or equal to 8 mg/dL) received 200 mg once-daily (qd) RDEA594, 400 mg qd RDEA594, 600 mg qd RDEA594 or matching placebo.

1 Apr 2010

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

31 Mar 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

ViroPharma Incorporated today announced that it has initiated an open-label, single-dose Phase 2 study to evaluate doses of Cinryze™ (C1 esterase inhibitor [human)] for treatment of acute angioedema attacks in children less than 12 years of age with hereditary angioedema.

31 Mar 2010

DSMB for DIGNITY trial recommends Celsion continue enrollment

Celsion Corporation announced today that after reviewing safety data from the 40mg/m2 cohort, the DIGNITY Study Drug Safety Monitoring Board (DSMB) has recommended that Celsion continue to enroll patients in the trial and that new patients be treated at a ThermoDox® dose of 50mg/m2.

31 Mar 2010

Cancer News and Research

Latest Cancer News and Research

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Role of membrane cholesterol in late keratinocyte differentiation analyzed

Thomson Reuters selects Rush University Medical Center as one of 100 Top Hospitals in the U.S.

Refinements to CTC-chip may better monitor how CTC levels react to prostate cancer treatment

Cell study may yield new treatment strategies for debilitating diseases

Link between occupational exposures and postmenopausal breast cancer

Dutasteride reduces risk of prostate cancer

Hormone ghrelin may improve appetite in gastric cancer patients

People in 60s and 70s more likely to be diagnosed with skin cancer

RPCI selects McKesson to manage its medical billing processes

Positive results from Phase 2 clinical trial of OMS103HP

New medicines to fight diseases of particular concern to African Americans

Court rules against gene patents

EMBL scientists identify genes involved in human cell division

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

Positive results from Ardea Biosciences' Phase 2b study of RDEA594 for hyperuricemia and gout

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

ViroPharma initiates Phase 2 clinical study to evaluate Cinryze

DSMB for DIGNITY trial recommends Celsion continue enrollment

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in